PMID- 28725273
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1758-5996 (Print)
IS  - 1758-5996 (Electronic)
IS  - 1758-5996 (Linking)
VI  - 9
DP  - 2017
TI  - A randomized controlled trial comparing the effects of dapagliflozin and DPP-4 
      inhibitors on glucose variability and metabolic parameters in patients with type 
      2 diabetes mellitus on insulin.
PG  - 54
LID - 10.1186/s13098-017-0255-8 [doi]
LID - 54
AB  - BACKGROUND: Dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium-glucose 
      co-transporter 2 (SGLT2) inhibitors improve hyperglycemia, and the usefulness of 
      co-administration of DPP-4 inhibitors and insulin therapy has been well 
      established. However, it has been still uncertain whether combination therapy of 
      SGLT2 inhibitors and insulin is superior to that of DPP-4 inhibitors and the 
      latter. Therefore, we investigated the superiority of dapagliflozin on glucose 
      fluctuation compared with DPP-4 inhibitors in patients with type 2 diabetes 
      mellitus (T2DM) on insulin using a continuous glucose monitoring (CGM) system. 
      METHODS: In this prospective, randomized, open-label controlled trial, 36 
      patients with T2DM and treated with DPP-4 inhibitors and insulin therapy, were 
      enrolled and allocated into two groups. The patients either switched their DPP-4 
      inhibitors to dapagliflozin 5 mg for 12 weeks, or continued their DPP-4 
      inhibitors for the same period. CGM analyses and metabolic markers were assessed 
      before and after treatment periods. RESULTS: In total, data from 29 patients were 
      analyzed. There were no significant differences in the mean amplitude of glycemic 
      excursions and other CGM profiles in either group after treatment. Within the 
      dapagliflozin treatment group, significant reductions of body mass index and 
      albuminuria, and increases of HbA1c, hemoglobin and hematocrit were observed, but 
      improvement of albuminuria was not significant if compared with the DPP-4 
      continuation group. CONCLUSIONS: Combination therapy of dapagliflozin and insulin 
      was not superior in glucose fluctuation to DPP-4 inhibitors on insulin. However, 
      dapagliflozin may in part provide favorable effects on metabolism in patients 
      with T2DM treated with insulin therapy. Trial registration UMIN-CTR: 
      UMIN000015033. Registered 2 September 2014.
FAU - Nomoto, Hiroshi
AU  - Nomoto H
AD  - Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and 
      Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-ku, 
      Sapporo, Hokkaido 060-8638 Japan. ISNI: 0000 0001 2173 7691. GRID: grid.39158.36
FAU - Miyoshi, Hideaki
AU  - Miyoshi H
AD  - Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and 
      Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-ku, 
      Sapporo, Hokkaido 060-8638 Japan. ISNI: 0000 0001 2173 7691. GRID: grid.39158.36
FAU - Sugawara, Hajime
AU  - Sugawara H
AD  - Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and 
      Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-ku, 
      Sapporo, Hokkaido 060-8638 Japan. ISNI: 0000 0001 2173 7691. GRID: grid.39158.36
FAU - Ono, Kota
AU  - Ono K
AD  - Clinical Research and Medical Innovation Center, Hokkaido University Hospital, 
      North 14, West 5, Kita-ku, Sapporo, Hokkaido 060-8648 Japan. ISNI: 0000 0004 0378 
      6088. GRID: grid.412167.7
FAU - Yanagiya, Shingo
AU  - Yanagiya S
AD  - Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and 
      Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-ku, 
      Sapporo, Hokkaido 060-8638 Japan. ISNI: 0000 0001 2173 7691. GRID: grid.39158.36
FAU - Oita, Mayuko
AU  - Oita M
AD  - Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and 
      Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-ku, 
      Sapporo, Hokkaido 060-8638 Japan. ISNI: 0000 0001 2173 7691. GRID: grid.39158.36
FAU - Nakamura, Akinobu
AU  - Nakamura A
AD  - Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and 
      Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-ku, 
      Sapporo, Hokkaido 060-8638 Japan. ISNI: 0000 0001 2173 7691. GRID: grid.39158.36
FAU - Atsumi, Tatsuya
AU  - Atsumi T
AD  - Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and 
      Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-ku, 
      Sapporo, Hokkaido 060-8638 Japan. ISNI: 0000 0001 2173 7691. GRID: grid.39158.36
LA  - eng
PT  - Journal Article
DEP - 20170717
PL  - England
TA  - Diabetol Metab Syndr
JT  - Diabetology & metabolic syndrome
JID - 101488958
PMC - PMC5514514
OTO - NOTNLM
OT  - Blood glucose fluctuation
OT  - Dipeptidyl peptidase-4 inhibitors
OT  - Sodium-glucose co-transporter 2 inhibitors
OT  - Type 2 diabetes mellitus
EDAT- 2017/07/21 06:00
MHDA- 2017/07/21 06:01
PMCR- 2017/07/17
CRDT- 2017/07/21 06:00
PHST- 2017/05/26 00:00 [received]
PHST- 2017/07/12 00:00 [accepted]
PHST- 2017/07/21 06:00 [entrez]
PHST- 2017/07/21 06:00 [pubmed]
PHST- 2017/07/21 06:01 [medline]
PHST- 2017/07/17 00:00 [pmc-release]
AID - 255 [pii]
AID - 10.1186/s13098-017-0255-8 [doi]
PST - epublish
SO  - Diabetol Metab Syndr. 2017 Jul 17;9:54. doi: 10.1186/s13098-017-0255-8. 
      eCollection 2017.